Home > News & Events > News
The Fourth Session of CJFH Association of Neuroendocrine Tumor Patients
Source: Posted Date:07-31-2018

On the morning of July 20th, 2018, the fourth session of CJFH Association of Neuroendocrine Tumor Patients, an event that has been supported by the hospital including the leadership, experts from the West campus and the multidisciplinary team, was held in the conference room located on the third floor of the campus building. Warmly received by patients and their families, this gathering attracted Mrs. Ding Jinghong, deputy party secretary and Mr. Jiang Kai, director of the West campus. Professor Li Peiwen, a leading expert in integrative oncology, Luo Jie, associate senior doctor from pathology, Zhang Minggang, associate senior doctor from the division of digestive diseases, associate senior doctor Meng Fanqiang, Drs. Liu Liguo and Zhang Guochao from general surgery, Dr. Dou Dou and six graduate students from integrative oncology, Ms. Yang Guiling, a head nurse from the 6th floor in the West campus, as well as patients and their families joined in the event. Chaired by Prof. Tan Huangying, director of the CJFH Center for Neuroendocrine Oncology, this session invited Professor Yu Jiangyuan, expert in nuclear medicine from Beijing Cancer Hospital, to deliver a report on the somatostatin receptor-mediated radionuclide therapy.
 
First of all, Mrs. Ding Jinghong delivered a welcome speech on behalf of CJFH, extending a warm welcome to all the patients and expressing her gratitude for their trust in the hospital. According to Mrs Ding, CJFH Center for Neuroendocrine Oncology belongs to the division of integrated Chinese and western medicine for oncology, relies on the CJFH multidisciplinary team of neuroendocrine oncology, and features in "standardized diagnosis and treatment, multidisciplinary collaboration and the integration of Chinese and western medicine". Highly praising Professor Tan Huangying’s team for their achievements in the diagnosis and treatment of neuroendocrine tumors, the deputy party secretary also encouraged the patients to cooperate with the doctors and lead a positive life. 
 
Mr. Jiang Kai also thanked the patients for their trust in the West campus of CJFH and promised to create a good environment for the patients by improving logistic support in the West campus.
 
Next, a number of experts in pathology, surgery, endoscopic treatment, PRRT, acupuncture, diet and psychology offered lectures on medical treatment and psychological support.
 
Professor Li Peiwen, a grand master of Chinese medicine and leading expert in integrative oncology, elaborated on the topic of diet, an issue that cancer patients are most concerned about. Professor Li stressed that unhealthy diet accounted for about 35% of all tumor cases, and a proper diet was essential to cancer treatment. A good diet for cancer patients was defined as "not too salty, not too exquisite, and not too oily", in other words, attention should be drawn to limiting animal fats, increasing coarse fiber, reducing meat, adding fresh fruits and vegetables as well as avoiding obesity.
 
Luo Jie, associate senior doctor from pathology with rich experience of NET, introduced the reason why pathological consultation was necessary for most neuroendocrine tumor patients. According to Doctor Luo, pathological diagnosis is the "gold standard" for tumors; however, pathological diagnosis can be subjective. Since neuroendocrine tumor is currently a rare tumor, it can be easily misdiagnosed as other diseases by inexperienced doctors and the entire treatment could be jeopardized. The enthusiastic and informative lecture by Dr Luo also explained the procedure in pathological diagnosis, and the preparation for pathology consultation.  
 
Professor Tan Huangying, from the department of integrated Chinese and western medicine for oncology, delivered a report on the causes of anxiety that neuroendocrine tumor patients underwent and means to cope with that situation. According to Professor Tan’s analysis, such anxiety stemmed from the lack of scientific dissemination developed by medical professionals and an overflow of misleading information on the internet, which leads to the patients’ misunderstanding of this type of tumor. Professor Tan stressed that scientific dissemination was the key and introduced the diagnosis and treatment principles for rectal neuroendocrine tumor, gastric neuroendocrine tumor and pancreatic neuroendocrine tumor.
Yu Jiangyuan, expert of nuclear medicine from Beijing Cancer Hospital, addressed the issues of what PRRT treatment is and whom PRRT is suitable for. Professor Yu talked about the definition of PRRT, that is, somatostatin receptor-mediated radionuclide therapy, the prerequisites for PRRT treatment, i.e. octreotide scan or 68Ga pet-ct positive, and the side effects of the procedure.
 
Dr Liu Liguo from general surgery focused on the surgical problems that neuroendocrine tumor patients are most concerned about. Emphasizing the importance of surgery in the treatment of neuroendocrine tumors with liver metastasis, Doctor Liu stressed that 40-95% of the patients are at the terminal stage of cancer on their hospital visit, and 65-95% of gastrointestinal NET patients also have liver metastasis upon their first hospital visit, however, even if there is liver metastasis, after surgery and multidisciplinary treatment, the 5-year survival rate can still reach 56%. 
Zhang Minggang, associate senior doctor from the division of digestive diseases, gave a lecture entitled "Application of EMR and ESD in Gastrointestinal Neuroendocrine Tumors".
 
According to Dr. Zhang, both EMR and ESD are endoscope treatments, while EMR is short for “endoscopic mucosal resection”, ESD is the acronym of “endoscopic submucosal dissection”. With picture illustration, he described the procedures for EMR and ESD treatment, along with their indications and possible complications. Dr. Zhang explained these complex medical concepts in plain terms, leaving a great impression on the patients.
 
Patients often ask if there is a feasible method in traditional Chinese medicine that is good for health and assists in the treatment of neuroendocrine tumors. Doctor Dou Dou, from integrated Chinese and western medicine for oncology, delivered a lecture entitled “Application of Traditional Chinese Medicine in Neuroendocrine Tumor Treatment-Acupuncture and Massage." Patients were intrigued by the vivid explanation of the principles of acupuncture and massage, the introduction of various massage techniques and several other treatments in traditional Chinese medicine including moxibustion, cupping, scraping and auricular points.
 
During the Q&A session between the lectures, patients put forward their questions and the experts addressed their problems with great patience. After such warm interaction, the patients recognized the great benefits that this meeting brought and expected to join in such event again in the future. A pamphlet entitled “ABCs of NET – Patient Education Manual” was prepared for this conference.
 
This year marks the fourth session of CJFH Association of Neuroendocrine Tumor Patients. The four sessions have not only built a platform for doctor-patient communication, dissemination of authoritative medical knowledge, refuting misleading internet information, but more importantly, lent psychological support to patients of this rare cancer, so that they can talk about their distress, pose questions, help each other, overcome loneliness and anxiety, and brighten their hope of recovery.
 
Chaired by Professor Tan Huangying, CJFH Center for Neuroendocrine Oncology was established on September 9, 2017 as part of the division of integrated Chinese and western medicine for oncology. The center relies on the CJFH multidisciplinary team of neuroendocrine oncology and features in "standardized diagnosis and treatment, multidisciplinary collaboration and the integration of Chinese and Western medicine". The neuroendocrine tumor MDT includes integrated Chinese and western medicine for oncology, pathology, gastroenterology, respiratory medicine, endocrine, general surgery, thoracic surgery, urology, radiology, nuclear medicine, radiation oncology and interventional ultrasound medicine.